Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:upadacitinib
|
| gptkbp:accessories |
prescription only
|
| gptkbp:activities |
Janus kinase inhibitor
|
| gptkbp:approves |
gptkb:2020
gptkb:United_States |
| gptkbp:brand |
gptkb:Rinvoq
|
| gptkbp:clinical_trial |
Phase 3
skin conditions autoimmune disorders chronic inflammatory conditions Rinvoq clinical trials gastrointestinal conditions |
| gptkbp:contraindication |
active infections
severe liver impairment history of thrombosis |
| gptkbp:developed_by |
gptkb:Abb_Vie
|
| gptkbp:dosage_form |
gptkb:tablet
|
| gptkbp:excretion |
urine
|
| gptkbp:formulation |
oral tablet
|
| gptkbp:has |
15 mg once daily
|
| https://www.w3.org/2000/01/rdf-schema#label |
upadacitinib acetate
|
| gptkbp:indication |
gptkb:Crohn's_disease
gptkb:ulcerative_colitis atopic dermatitis |
| gptkbp:ingredients |
C17 H20 N6 O3 S
|
| gptkbp:interacts_with |
live vaccines
other immunosuppressants CY P450 inducers CY P450 inhibitors |
| gptkbp:invention |
patented
|
| gptkbp:is_used_for |
gptkb:rheumatoid_arthritis
|
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
gptkb:Rinvoq
|
| gptkbp:metabolism |
liver
|
| gptkbp:research_areas |
autoimmune diseases
dermatology inflammatory diseases gastroenterology |
| gptkbp:safety_features |
Category C
|
| gptkbp:side_effect |
fatigue
headache nausea cardiovascular events thrombosis malignancy risk serious infections gastrointestinal perforations increased liver enzymes upper respiratory tract infections |